Gilead Sciences (GILD) Finished Goods (2009 - 2015)
Gilead Sciences (GILD) reported Finished Goods of $852.0 million for Q4 2015, up 82.83% on a YoY basis from $466.0 million in Q4 2014, and up 82.83% quarter-over-quarter from $466.0 million in Q4 2014.
Gilead Sciences (GILD) Finished Goods (2009 - 2015) Analysis & Trends
Gilead Sciences has reported Finished Goods for 7 years, with the latest figure at $852.0 million in Q4 2015.
- For the quarter ending Q4 2015, Finished Goods rose 82.83% year-over-year to $852.0 million; the trailing twelve-month figure through Dec 2015 stood at $852.0 million (up 82.83% YoY), and the FY2015 full-year result was $852.0 million, up 82.83% from the prior year.
- Finished Goods for Q4 2015 stood at $852.0 million, up from $466.0 million in the prior quarter.
- The five-year high for Finished Goods was $852.0 million in Q4 2015, with the low at $225.9 million in Q4 2011.
- Historically, Finished Goods has averaged $487.3 million across 5 years, with a median of $466.0 million in 2014.
- Annual changes were most pronounced in 2011 — Finished Goods sank 33.79% — and 2012, when it jumped 147.9%.
- Gilead Sciences' Finished Goods stood at $225.9 million in 2011, then jumped by 147.9% to $559.9 million in 2012, then increased by 5.99% to $593.4 million in 2013, then retreated by 21.47% to $466.0 million in 2014, then soared by 82.83% to $852.0 million in 2015.
- The last three Finished Goods figures came in at $852.0 million (Q4 2015), $466.0 million (Q4 2014), and $560.0 million (Q2 2014), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 852.00 Mn |
| Dec 31, 2014 | 466.00 Mn |
| Jun 30, 2014 | 559.98 Mn |
| Dec 31, 2013 | 593.44 Mn |
| Dec 31, 2012 | 559.91 Mn |
| Dec 31, 2011 | 225.86 Mn |
| Sep 30, 2011 | 295.79 Mn |
| Jun 30, 2011 | 384.72 Mn |
| Mar 31, 2011 | 448.43 Mn |
| Dec 31, 2010 | 341.14 Mn |
| Sep 30, 2010 | 439.32 Mn |
| Dec 31, 2009 | 326.15 Mn |